E6Dp53

E6Dp53 is a therapeutic stapled peptide developed for the treatment of Human Papillomavirus (HPV)-associated malignancies, including cervical and head and neck cancers. The drug functions by disrupting the interaction between the viral E6 oncoprotein and the host tumor suppressor protein p53. In HPV-infected cells, E6 recruits the E6AP ubiquitin ligase to target p53 for rapid degradation, thereby bypassing cell cycle checkpoints and preventing apoptosis. E6Dp53, which is modeled after the p53 helix that binds E6, competitively occupies the E6 binding pocket. This stabilization of p53 restores its transcriptional activity, leading to the induction of p21-mediated growth arrest and apoptosis specifically in HPV-positive cancer cells. This targeted approach aims to selectively eliminate malignant cells while minimizing effects on healthy, non-infected tissues.

Other names

E6-binding p53-derived peptideE-6-binding p53-derived peptideE 6-binding p53-derived peptidep53-derived stapled peptidep-53-derived stapled peptidep 53-derived stapled peptide